Arundic Acid as a Selective Inhibitor of the S100B Protein in Glioblastoma

Introduction

Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor in adults, accounting for approximately 45% of all malignant brain tumors. Despite aggressive treatment, utilizing surgical resection, radiotherapy, and temozolomide chemotherapy, the prognosis still has a median survival rate of 12-15 months, and a 5-year survival rate of approximately 10%. (Singh, S., et al., 2025) The therapeutic challenge of GBM is grounded in numerous factors, including a highly infiltrative nature, as profound intratumoral heterogeneity, immunosuppressive tumor microenvironment, and strong therapeutic resistance. (Shellenbarger, P., 2024)

Some recent molecular profiling studies have shown that GBM exhibits complex cellular heterogeneity comprising of at least four interconvertible cell states: astrocyte-like, neural progenitor-like, oligodendrocyte progenitor-like, mesenchymal-like populations. These cellular states spatially organize within distinct microanatomical niches, including perivascular, hypoxic, and invasive regions, each characterized by unique metabolic and transcriptional programs. (Prakash, P., et al., 2026) This adaptability allows GBM cells to continuously respond to therapeutic pressures and microenvironmental alterations

The S100 protein family has emerged as a pivotal regulator of glioma progression and the tumor microenvironment. (Hu, Yifang, et al., 2021) (Zhang, Z., 2022) S100B is a calcium-binding protein that is predominately expressed by astrocytes and is associated with significant risk of gliomas. (6) Extracellular S100B functions as a damage-associated molecular pattern (DAMP) molecule that modulates immune cell function, promotes the recruitment of tumor-associated macrophages, facilitates glioma cell proliferation and invasion (7, 8). Elevated serum S100B levels correlate with poor prognosis in glioma patients, suggesting its potential as both a biomarker and therapeutic target. (4, 5)

Arundic acid represents a novel pharmacological approach to modulating astrocyte activation and S100B expression. (9, 10) Originally developed as a neuroprotective agent for ischemic stroke, arundic acid inhibits the enhanced synthesis of S100B protein in activated astrocytes, thereby attenuating neuroinflammatory cascades and reducing secondary brain injury. (11, 12)



Figure 1. Arundic acid ($C_{11}H_{22}O_2$)

Given the critical role of S10B in glioblastoma pathogenesis, arundic acid presents a rational therapeutic candidate for targeting GBM tumor microenvironment and potentially disrupting the complex interplay between tumor cells and their supportive astrocytic niche.

S100B Protein: Structure, Function, and Role in Glioblastoma

S100B Protein Biochemistry

S100B belongs to the S100 protein family, comprising of 25 members characterized by the presence of two calcium-binding EF-hand motifs. (4, 5) S100B exists primarily as a homodimer with a molecular weight of sapprocimatley 21 kDa and is predominantly expressed in astrocytes, oligodendrocytes, and specific neuronal populations within the central nervous system. (17) The protein functions as a calcium sensor and signaling transducer, with its biologicval activity depending on intracellular and extracellular calcium concentrations.

Upon calcium binding, S100B undergoes conformational changes that expose hydrophobic surfaces, enabling interaction with diverse target proteins involved in cellular processes including:

- Cell cycle progression and proliferation
- Cytoskeletal dynamics
- Enzyme activity modulation
- Transcription factor regulation

Apoptic Pathway Modulation

At low nanomolar concentrations, S100B exerts neurotrophic and neuroprotective effects, facilitating neuronal survival and neuritis extension. (17) Conversely, at elevated micromolar concentrations, extracellular S100B functions as a pro-inflammatory damage-associated molecular pattern (DAMP) molecule. This action triggers inflammatory cascades by activating pattern recognition receptors, notably the receptor for advanced glycation end products (RAGE) and Toll-like receptor 4 (TLR4). (8)

S100B Overexpression in Glioblastoma

Numerous studies have established significant overexpression of S100B in glioblastoma tissue and patient serum in comparison to lower-grade gliomas and healthy controls. (4, 5) Gene expression profiling and immunohistochemical analysis reveal a direct correlation between S100B expression and patient survival, with high S100B levels associated with shorter overall survival and progression-free survival. (4) S100B family-based gene signatures have been validated as independent prognostic factors in both The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) datasets. (4, 5)

S100B expression in glioblastoma exhibits spatial heterogeneity, with particularly high levels observed in:

1. Tumor-associated astrocytes within the tumor microenvironment
2. Reactive astrocytes at the tumor-brain interface
3. Subpopulations of GBM cells with astrocytic-like characteristics

4. Perivascular niches enriched with astrocytic components

Mechanisms of S100B-Mediated Glioblastoma Progression

S100B contributes to glioblastoma pathogenesis through multiple molecular mechanisms:

Promotion of Tumor Cell Proliferation and Invasion

In vitro studies demonstrate that S100B directly promotes GBM cell proliferation and migration through activation of RAGE-dependent signaling pathways. Knockdown of S100B using shRNA technology significantly inhibits GBM cell invasion and migration capabilities and reduces tumor growth in orthotopic xenograph models. S100B activates transforming growth factor-beta 2 **(TGF-β2)** signaling, which promotes epithelial-mesenchymal transition (EMT)-like processes in GBM cells, enhancing their invasive phenotype. (18)

Modulation of the Tumor Immune Microenvironment

S100B plays a pivotal role in the progression of glioblastoma multiforme (GBM) by acting as a chemoattractant for myeloid-derived cells, particularly tumor-associated macrophages (TAMs). Extracellular S100B secreted by GBM cells and reactive astrocytes recruits bone marrow-derived monocytes and promotes their infiltration into the tumor mass. (7) Once recruited, these myeloid cells undergo polarization toward an immunosuppressive M2-like phenotype rather than a tumoricidal M1 phenotype.

The S100B-mediated recruitment and polarization of TAMs create an immunosuppressive microenvironment that:

- Suppresses cytotoxic T cell function and natural killer (NK) cell activity.
- Promotes angiogenesis through the secretion of vascular endothelial growth factor (VEGF).
- Facilitates tumor cell survival and proliferation.
- Enhances therapeutic resistance by creating a protective niche.

Experimental studies in murine glioma models demonstrate that S100B downregulation significantly reduces macrophage infiltration, alters the ratio of M1 to M2 macrophages, and inhibits tumor growth. (7, 8) These findings establish S100B as a critical mediator linking tumor cells with the immunosuppressive microenvironment characteristic of GBM.

Astrocyte Activation and Reactive Gliosis

S100B overexpression induces reactive astrogliosis in peritumoral brain regions, characterized by astrocyte hypertrophy, proliferation, and upregulation of glial fibrillary acidic protein (GFAP). (19) This reactive astrocyte population contributes to GBM progression by secreting growth factors, cytokines, and extracellular matrix components that support tumor cell survival and invasion. (20) Activated astrocytes also exhibit altered glutamate metabolism, creating an excitotoxic environment that facilitates tumor expansion.

Mechanism of Action: Arundic Acid as an S100B Synthesis Inhibitor

Molecular Mechanism of S100B Inhibition

Arundic acid functions as a selective inhibitor of S100B protein synthesis in activated astrocytes, rather than a direct antagonist of the S100B protein itself. (9, 10, 11) The compound does not interfere with S100B protein function or receptor binding but instead prevents the enhanced transcription and translation of S100B that occurs during astrocyte activation.

The precise molecular mechanism by which arundic acid suppresses S100B synthesis involves modulation of astrocyte-specific transcriptional programs. In cultured astrocytes treated with pro-inflammatory stimuli (such as lipopolysaccharide, cytokines, or hypoxic conditions), arundic acid prevents the upregulation of S100B mRNA and subsequent protein expression. (10, 11) This inhibitory effect is concentration-dependent, with maximal suppression observed at concentrations of 1-10 μM in vitro.

Key features of arundic acid's mechanism include:

- **Selectivity:** Arundic acid preferentially targets activated astrocytes with minimal effects on resting astrocytes or neurons
- **Transcriptional regulation:** The compound interferes with S100B gene transcription, likely through modulation of transcription factors such as NFκB or STAT3
- **Intracellular Action:** The lipophilic nature of arundic acid facilitates cellular uptake, allowing it to exert its effects on intracellular signaling pathways.
- **Sustained Effect:** The suppression of S100B persists throughout the duration of arundic acid exposure, indicating stable transcriptional repression.

Effects on S100B Protein Levels

Experimental studies in brain injury models demonstrate that arundic acid significantly reduces both intracellular and extracellular S100B levels. (10, 11, 12) In rat models of intracerebral hemorrhage, arundic acid administration (20-30 mg/kg/day) reduced S100B protein expression by approximately 40-60% in affected regions. (12) Immunohistochemical analysis revealed decreased S100B immunoreactivity in reactive astrocytes surrounding lesion sites, accompanied by corresponding reductions in serum S100B levels.

Time-course studies indicate that arundic acid’s effect on S100B suppression occurs within 6-12 hours of administration and reaches maximum efficacy at 24-48 hours. (11) The effect is reversible upon drug withdrawal, with S100B levels gradually returning to baseline over 3-5 days. This suggests that arundic acid does not permanently alter astrocyte function but rather provides transient modulation during critical therapeutic windows.

Downstream Effects on Neuroinflammation and Cell Survival

By preventing S100B overexpression, arundic acid disrupts multiple pathological cascades associated with neuroinflammation and secondary brain injury:

Reduced Neuroinflammatory Signaling

S100B inhibition by arundic acid diminishes activation of RAGE and TLR4 receptors on microglia and peripheral immune cells, thereby reducing pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). (11, 12) This anti-inflammatory effect contributes to decreased microglial activation, reduced oxidative stress, and preservation of the blood-brain barrier integrity.

Modulation of Astrocyte Reactivity

Arundic acid treatment attenuates the reactive astrocytic phenotype, as evidenced by reduced GFAP expression and decreased astrocyte proliferation in injured brain regions. Morphometric analysis indicates that arundic acid-treated astrocytes maintain more physiological morphology with less hypertrophy and process retraction compared to control conditions. (19)

Neuroprotective Effects

Numerous experimental paradigms demonstrate that arundic acid provides neuroprotection through the suppression of S100B. In models of:

- Ischemic stroke: Arundic acid diminishes infarct volume, prevents delayed infarct expansion, and enhances neurological outcomes when administered within 24 hours of stroke onset. (16, 21)
- Intracerebral hemorrhage: Treatment with arundic acid decreases lesion size, reduces neurological deficits, and improves motor function recovery. (12)
- Parkinson's disease models: Arundic acid safeguards dopaminergic neurons from MPTP-induced neurotoxicity. (22)
- Alzheimer's disease models: The compound reduces amyloid plaque-associated gliosis and improves cognitive function in transgenic mice. (23)

Pharmacological Profile

Arundic acid exhibits favorable pharmacological properties for central nervous system applications:

Parameter	Value/Characteristic
Blood-brain barrier penetration	Good (lipophilic compound
Half-life (rodents)	2-4 hours
Dosing regimen (preclinical)	10-100 mg/kg/day
Route of administration	Intravenous, intraperitoneal, oral
Therapeutic window	0-24 hours post injury (acute models)
Safety profile	Well-tolerated in Phase I/II trials

Table 1: Pharmacological characteristics of arundic acid

Therapeutic Potential in Glioblastoma

Rationale for Arundic Acid in GBM Treatment

The therapeutic rationale for applying arundic acid to glioblastoma treatment rests on several key considerations:

Targeting the S100B-Mediated Immunosuppressive Microenvironment:

Given that S100B functions as a critical chemoattractant and polarization signal for immunosuppressive myeloid cells, (7, 8) arundic acid-mediated S100B suppression could potentially:

* Reduce recruitment of tumor-associated macrophages to the GBM microenvironment.
* Shift macrophage polarization from immunosuppressive M2 toward tumoricidal M1 phenotypes.
* Enhance anti-tumor immune responses by reducing immunosuppressive signaling.
* Improve efficacy of immunotherapeutic approaches by creating a more favorable immune milieu.

Inhibition of S100B-Driven Tumor Cell Proliferation and Invasion:

Direct anti-proliferative and anti-invasive effects of S100B inhibition have been demonstrated in GBM cell lines. (18) By preventing S100B synthesis in both tumor cells and tumor-associated astrocytes, arundic acid could potentially:

* Reduce tumor cell proliferation.
* Inhibit tumor cell invasion.

Preclinical Studies:

Preclinical studies using duloxetine, another S100B synthesis inhibitor, demonstrated that S100B suppression in orthotopic glioma models significantly reduced macrophage infiltration, altered macrophage polarization, and inhibited tumor growth. These proof-of-concept studies establish that S100B represents a viable therapeutic target in GBM, validating the potential utility of arundic acid.

Targeting Reactive Astrocytes in the Tumor Microenvironment

Non-neoplastic reactive astrocytes surrounding glioblastoma multiforme (GBM) contribute significantly to tumor progression by providing metabolic support, growth factors, and structural scaffolding for tumor expansion. (20) Recent studies demonstrate that reactive astrocytes transfer mitochondria to GBM cells, conferring enhanced respiratory capacity and therapeutic resistance. (24) By modulating astrocyte activation through S100B suppression, arundic acid could disrupt these supportive interactions between reactive astrocytes and tumor cells.

Preclinical Evidence and Experimental Considerations

Although direct preclinical studies specifically testing arundic acid in GBM models are limited, several lines of evidence support its therapeutic potential:

S100B Inhibition Studies in Glioma Models

Research demonstrating that pharmacological S100B inhibition with duloxetine reduces glioma growth in orthotopic mouse models provides proof-of-concept for this therapeutic approach. (8) In these studies, S100B inhibition (30 mg/kg for 14 days) significantly reduced tumor volume, altered the immune microenvironment, and improved survival outcomes. These findings strongly suggest that arundic acid, with its established safety profile and more specific mechanism targeting astrocytic S100B synthesis, could provide similar or superior efficacy.

S100B Genetic Knockdown Studies

Genetic approaches employing shRNA-mediated S100B knockdown in GBM cells demonstrate that S100B reduction inhibits tumor growth in vivo without affecting proliferation in vitro. This observation suggests that the primary anti-tumor effects of S100B suppression originate from microenvironmental modulation rather than direct cytotoxic effects on tumor cells. Notably, S100B knockdown exhibited no impact on GBM cell division in culture but significantly inhibited tumor growth in orthopedic xenographs, underscoring the pivotal role of the tumor microenvironment. (7)

Comparative Studies with Other Astrocyte Modulators

Other compounds targeting astrocyte activation and members of the S100 family of proteins have demonstrated promise in GBM models. These include agents that modulate astrocytic glutamate metabolism, inhibit reactive gliosis, or alter astrocyte-tumor cell communication. The convergence of evidence from these diverse approaches supports the general strategy of targeting astrocytic dysfunction in GBM therapy.

Potential Combination Strategies

Arundic acid's mechanism of action suggests potential synergy with established and emerging GBM therapies:

Combination with Immunotherapy

The immunosuppressive microenvironment presents a significant impediment to effective immunotherapy in GBM. Checkpoint inhibitors (anti-PD-1, anti-CTLA-4) have demonstrated limited efficacy in GBM, partly due to inadequate T cell infiltration and activation in myeloid populations. (25) Arundic acid could potentially augment immunotherapy efficacy by:

-Reducing TAM-mediated immunosuppression
-Enhancing T cell infiltration and activation
-Creating a more inflammatory tumor microenvironment receptive to immune checkpoint blockade
-Modulating astrocyte-mediated immune exclusion mechanisms

Combination with Standard Chemotherapy

Temozolomide, the standard chemotherapeutic agent for glioblastoma multiforme (GBM), induces DNA alkylation and cell death but also triggers reactive astrogliosis and S100B upregulation as part of the tissue damage response. (26) Co-administration of arundic acid with temozolomide could potentially:

1. Suppress chemotherapy-induced S100B elevation and associated inflammatory responses.
2. Reduce treatment-related brain edema and secondary injury.
3. Enhance drug penetration by modulating the reactive astrocytic barrier.
4. Reduce tumor cell survival signals mediated by S100B.

Combination with Radiation Therapy

Radiation-induced astrocyte activation and S100B upregulation contribute to delayed radiation injury and cognitive decline in GBM patients receiving whole-brain radiotherapy. (27) Arundic acid administration during radiation treatment could provide neuroprotection while potentially enhancing tumor response through microenvironmental modulation.

Clinical Translation Considerations

Several factors support the clinical translation of arundic acid for GBM treatment:

Established Safety Profile

Phase I and Phase II clinical trials of arundic acid in acute ischemic stroke patients have demonstrated acceptable safety and tolerability. (16) No serious adverse events related to the drug mechanism were observed at doses up to 12 mg/kg/hour administered intravenously. This established safety database reduces the translational risk for GBM applications.

Blood-Brain Barrier Penetration

Arundic acid's lipophilic properties facilitate its penetration of the blood-brain barrier, a crucial prerequisite for drug therapies targeting brain tumors. (15) In contrast to large molecule biologics that necessitate disruption of the blood-brain barrier, arundic acid can attain therapeutic concentrations in brain tissue through passive diffusion.

Biomarker-Guided Approach

Serum S100B levels serve as a readily accessible biomarker for patient selection and therapeutic monitoring. (4, 5) GBM patients exhibiting elevated serum S100B levels could be prioritized for arundic acid therapy. Serial measurements of S100B levels could guide dose optimization and assess pharmacodynamic effects.

Potential for Repurposing

Given that arundic acid has undergone clinical development for stroke indications, repurposing this compound for GBM treatment could expedite the path to clinical testing. The extensive

preclinical pharmacology, toxicology, and early-phase clinical data available for arundic acid substantially mitigate its development risks for oncology applications.

Challenges and Future Directions

Current Knowledge Gaps

Several critical questions require investigation before arundic acid can be effectively de

Efficacy in GBM-Specific Models

Direct testing of arundic acid in orthotopic GBM xenograft models and genetically engineered mouse models is essential to establish its efficacy. These studies should:

- Evaluate tumor growth inhibition at clinically relevant doses.
- Assess effects on survival endpoints.
- Characterize changes in the tumor immune microenvironment.
- Determine optimal dosing regimens and treatment schedules.
- Test combination strategies with standard-of-care therapies.

Mechanism of Resistance

Given GBM's notorious capacity for developing therapeutic resistance, potential mechanisms of resistance to S100B inhibition must be anticipated:

1. Compensatory upregulation of other S100 family members (S100A4, S100A8/A9) that may substitute for S100B functions.
2. Alternative pathways for macrophage recruitment and polarization independent of S100B.
3. Metabolic adaptations that circumvent S100B-mediated signaling.
4. Tumor cell state transitions that reduce dependence on S100B signaling.

Optimal Patient Selection

Not all glioblastoma multiforme (GBM) patients exhibit elevated S100B expression, and the correlation between S100B levels, tumor genetics, and therapeutic response remains elusive. Biomarker studies should elucidate the following:

-Identification of molecular GBM subtypes with the highest S100B expression.
-Establishment of a correlation between tumor S100B levels, serum S100B, and clinical outcomes.
-Development of predictive biomarkers for arundic acid response.
-Characterization of changes in S100B expression during tumor recurrence and treatment.

Works Cited

[1] Glioblastoma at the crossroads: current understanding and future directions. (2025). *Nature*. https://www.nature.com/articles/s41392-025-02299-4

[2] MSU researchers nd early, promising glioblastoma treatment. (2024). *MSU Today*. https://msutoday.msu.edu/news/2024/01/msu-researchers-nd-early-promising-glioblastoma-treatment

[3] Prakash, P., Trippett, J., Ehsan, C., et al. (2026). Tumor microenvironment shapes the spatial organization of glioblastomacell states. *Neuro-Oncology*, noag003. https://doi.org/10.1093/neuonc/noag003

[4] Yifang, H., Jiahang, S., Zhen, W., et al. (2021). A Novel S100 Family- Based Signature Associated with Prognosis and Immune Microenvironment in Glioma. *Oncology*, 29. https://onlinelibrary.wiley.com/doi/10.1155/2021/3586589

[5] Wang, L., Lv, P., & Lou, Y. (2022). Alarm Signal S100-Related Signature Is Correlated with Tumor Microenvironment and Predicts Prognosis in Glioma. *Disease Markers*, 2022, 4968555. https://doi.org/10.1155/2022/4968555

[6] The Role of the S100 Protein Family in Glioma. (2022). *Journal of Cancer*, 13(10), 3022-3030. https://www.jcancer.org/v13p3022.htm

[7] Wang, H., Zhang, L., Zhang, I. Y., et al. (2013). S100B Promotes Glioma Growth through Chemoattraction of Myeloid-Derived Macrophages. *Clinical Cancer Research*, 19(14), 3764-3775. https://doi.org/10.1158/1078-0432.CCR-12-3725

[8] Gao, H., Zhang, I. Y., Zhang, L., et al. (2018). S100B suppression alters polarization of inltrating myeloid-derived cells in gliomas and inhibits tumor growth. *Cancer Letters*, 439, 91-100. https://doi.org/10.1016/j.canlet.2018.07.034

[9] ONO-2506 Product Information. (2025). *Sigma-Aldrich*. https://www.sigmaaldrich.com/US/en/product/sigma/sml2896

[10] Arundic Acid (ONO-2506) Attenuates Neuroinammation. (2020). *Cell and Molecular Neurobiology*, 42(3), 739-751. https://doi.org/10.1007/s10571-020-00964-6

[11] Hao, M. M., Capoccia, E., Cirillo, C., et al. (2017). Arundic Acid Prevents Developmental Upregulation of S100B Expression and Inhibits Enteric Glial Development. *Frontiers in Cellular Neuroscience*, 11, 42. https://doi.org/10.3389/fncel.2017.00042

[12] Cordeiro, J. L., Neves, J. D., Vizuete, A. F., et al. (2020). Arundic Acid (ONO-2506), an Inhibitor of S100B Protein Synthesis, Prevents Neurological Decits and Brain Tissue Damage Following Intracerebral Hemorrhage. *Neuroscience*, 440, 97-112. https://doi.org/10.1016/j.neuroscience.2020.05.030

[15] Arundic Acid a Potential Neuroprotective Agent: Biological Development and Syntheses. (2013). *Current Medicinal Chemistry*, 20(18), 2315-2329. https://doi.org/10.2174/0929867311320180003

[16] Pettigrew, L. C., Kasner, S. E., Albers, G. W., et al. (2006). Safety and tolerability of arundic acid in acute ischemic stroke. *Journal of the Neurological Sciences*, 251(1-2), 50-56. https://doi.org/10.1016/j.jns.2006.09.001

[17] The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker. (2023). *PLOS Biology*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10253509/

[18] S100B drives glioblastoma invasion and migration through TGF- β2. (2025). *Spandidos Publications*. https://www.spandidos-publications.com/10.3892/or.2025.9025

[19] Higashino, H., Niwa, A., Satou, T., et al. (2009). Immunohistochemical analysis of brain lesions using S100B and glial brillary acidic protein antibodies in arundic acid-treated stroke- prone spontaneously hypertensive rats. *Cell and Tissue Research*, 337, 351-365. https://d-nb.info/1190791552/34

[20] Identication and characterization of tumor-associated astrocytes. (2025). *PLOS Biology*. https://journals.plos.org/plosbiology/article/gures?id=10.1371%2Fjournal.pbio.3002893

[21] Tateishi, N., et al. (2002). Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. *Journal of Cerebral Blood Flow & Metabolism*, 22, 723-734. PMID: 12045671

[22] Kato, S., et al. (2004). Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity inmice. *Brain Research*, 1030, 66-73. PMID: 15567338

[25] IMPS-44: S100B Inhibition with Duloxetine. (2015). *Neuro-Oncology*, 17(Suppl 5), v122-v123. https://doi.org/10.1093/neuonc/nov217.43

[26] Arundic acid (ONO-2526) inhibits stimulated-S100B secretion. (2021). *Neuroscience Letters*. https://www.sciencedirect.com/science/article/abs/pii/S0304394021001543

[27] Neuroprotective eect of arundic acid on Cynomolgus macaques with cerebral ischemia-reperfusion injury. (2024). *Chinese Journal of Pharmacology and Toxicology*, 38(4). https://cjpt.magtechjournal.com/EN/10.3867/j.issn.1000-3002.2024.04.001